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After odontogenic pain, temporomandibular disorders (TMDs)
are one of the most common causes of pain in the mouth and
face and also have the potential to produce persisting (chronic)
pain.1 2 Chronic or persistent (myogenous) TMDs can be
associated with other chronic pain conditions,3 including
migraine, fibromyalgia, and widespread pain.4-8 They are also
known to be comorbid with bruxism, depression, irritable bowel
syndrome, and chronic fatigue.6 9 10 With or without these
comorbidities, TMDs are recognised to have a considerable
impact on quality of life.11-17
Early diagnosis and explanation followed by management is
likely to be key to improving prognosis and reducing the impact
of this group of conditions on quality of life.11 18 The purpose
of this review is to give non-specialists an overview of the
diagnosis and management of TMDs.
What are TMDs?
Some of the signs and symptoms suggestive of TMDs were
identified back in the 1930s by Costen, who incorrectly
attributed them to changes in occlusion (bite of the teeth).19Over
the next 80 years the terminology has changed and been revised
several times20-22 until the collective term temporomandibular
disorders has been accepted.23-26 The most widely accepted
definition is “a group of musculoskeletal . . . conditions that
involve the temporomandibular joints (TMJs), the masticatory
muscles and all associated tissues.”27Anew expanded taxonomy
is now available defining the various subtypes of disorder or
disease incorporated in this group.28
How common are TMDs and who gets
them?
Data from a US large and ongoing prospective cohort study
(OPPERA)29 suggest that the incidence of first onset painful
TMDs is 3-4% per annum. Among the population studied (adults
aged 18-44) for first onset of painful TMDs there seemed to be
only a slight preponderance for women to be affected more than
men (imputed hazard ratio 1.3, P>0.05) and an increasing
incidence with age: 18-24 age band 2.5%, 25-34 age band 3.7%,
and 35-44 age band 4.5%.30 The probability of first onset TMDs
is also strongly associated with concurrent headaches and body
pain.31 32 The prevalence of painful TMDs in adolescents is still
a matter of debate,33 with some estimates reaching 25%, but in
developed countries it is estimated to be between 2% and 6%.34-36
In adults aged more than 45 the prevalence of painful TMDs is
likely to lie in the range of 2-7%,37 although estimates vary and
those aged over 45 are more likely to display objective signs of
TMDs but be asymptomatic.38
Among all incident cases in the OPPERA study, pain occurred
as a singular episode in 12%, recurrent episode in 65%, and
persistent episode in 19%. Pain was most commonly reported
in both the joint and the muscles of mastication (arthralgia with
myalgia: 73% of the incident cases); the next most common
presentation was myalgia alone (23% of incident cases).30
OPPERA and other US data suggest there is a disproportionate
increase in healthcare utilisation with TMDs.32 39 The reasons
behind this are not fully explained, but ongoing research40 in
the United Kingdom seeking to determine the effectiveness and
efficacy of care pathways for orofacial pain (http://research.ncl.
ac.uk/deepstudy) may help to explain this from a UK context
in due course.
What causes TMDs?
The causes and underlying pathophysiology of TMDs have been
the subject of much debate and some controversy over the
years.26 41 It is suggested that the cause is likely to be both
multifactorial and biopsychosocial, consisting of initiating,
predisposing, and perpetuating factors, for example,
macro-trauma or micro-trauma, linked to a failure to heal
appropriately because of the underlying psychosocial profile of
the patient, failed treatment, or genotype.41-43 Evidence is now
emerging for factors involved in the complex multifactorial
pathophysiology of TMDs relating to both genotype and
phenotype.44 45
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The bottom line
TMDs represent a range of conditions with multifactorial complex pathophysiology, which are common up to the age of 40 years
TMDs can present as a continuous or episodic pain of varying intensity around and in the ears radiating up to the temple or down the
mandible to the neck
Persistent (chronic) TMDs can be associated with other chronic pain conditions
Early management with education and counselling is highly effective
More complex patients or those with persistent TMDs require a biopsychosocial approach delivered by a multidisciplinary pain team
Sources and selection criteria
We conducted a systematic search of Medline (1966 to 5 August 2014), PROSPERO, and Cochrane libraries for systematic reviews relating
to interventions for TMDs. For systematic reviews in Medline we used the search strategy suggested by BMJ Clinical Evidence search
strategy. We searched PROSPERO and Cochrane libraries using their own search engines with the terms “temporomandibular”,
“temporomandibular disorder”, “temporomandibular joint”, and “pain dysfunction syndrome”. The supplementary table summarises the most
recent and relevant systematic reviews. It excludes older systematic reviews that duplicate more recent ones unless they are within a five
year period and offer contradictory evidence. All Cochrane reviews identified are contained within the summary table.
In recent years major advances have occurred in the knowledge
of the underlying pathophysiology of TMDs. It is suggested
that women with an oestrogen receptor polymorphism have
twice and three times the odds of developing a non-painful or
painful TMD, respectively, compared with women without the
polymorphism.46 Several studies suggest the pain of TMDs to
be potentially mediated by several different mechanisms: central
sensitisation, through neuroplasticity and calcitonin gene related
peptide,47-51 and differing haplotypes of the gene encoding
catecholamine-O-methyltransferase, which produce less activity
of this enzyme.52 53 Some of the neural abnormalities detected
in chronic TMDs are in the trigeminal and limbic systems,54 and
cortical activity may be changed such that cognitive and
emotional tasks are harder to perform.55
Further to this genetic polymorphisms in the folate and oxidative
metabolic pathways may be associated with oxidative stress
and be implicated in degenerative joint disease.56-58 Such disease
has also been associated with a metalloproteinase gene
polymorphism.59
Clearly there may be further advances in the coming years, but
what is truly exciting are the potential advances in identifying
targets for treatment, such as calcitonin gene related peptide
and β adrenergic receptors. β Adrenergic receptors have already
been shown in a proof of concept trial to be of benefit if targeted
by treatment.60
What are the clinical features?
TMDs can present with any or all of the following signs and
symptoms: pain in the temporomandibular joint or muscles of
mastication (figures 1⇓ and 2⇓), which may radiate or refer to
local or distant structures; clicking, popping, or crepitus of the
temporomandibular joint on any of its movements with or
without locking of the joint; headache limited to the temporal
region61; and otalgia or tinnitus, or both in the absence of aural
disease. The correlation between self reported severity of pain
and pathological changes in the joints or muscles is poor.26
The table⇓ summarises the 12 most common TMDs and the
most salient points of their history and examination findings.
Some patients present principally with a self reported painless
clicking (disc displacement with reduction) and are mistakenly
concerned that this indicates damage. Others report episodic
painful (closed) locking, an inability to open the mouth wide
(disc displacement with reduction with intermittent limited
opening), persistent closed lock (disc displacement without
reduction with limited opening), or repeated dislocation of the
temporomandibular joint, which are all clearly of functional
importance.
How are TMDs diagnosed?
Over the past two decades progress in revising and validating
the diagnostic criteria for TMDs has been considerable.62-74 In
their validated and revised form these criteria, originally known
as the RDC/TMD (Research Diagnostic Criteria for TMD),62
are now known as the DC/TMD (Diagnostic Criteria for TMD).75
They provide a standard and operationalised manner in which
to examine the temporomandibular joint and its associated
structures (axis 1) physically and to screen for psychosocial
comorbidity (axis 2).
A simple method to screen for painful TMDs (as a physical
entity) is to use a six item self complete questionnaire developed
in tandem with the Diagnostic Criteria for TMD.76 When used
in a facial pain clinic this method has 99% sensitivity and 98%
specificity for painful TMDs and may be of utility in busy
general medical practices. The questionnaire is freely available
on the RDC/TMD consortium’s website (www.rdc-
tmdinternational.org/OtherInstruments/TMDPainScreener.aspx).
A score of 3 or more is indicative of a positive screening for
TMDs. Alternatively the questions posed could be incorporated
into a standard clinical history for orofacial pain.
Axis 1
The physical axis of the DC/TMD, axis 1, defines 38 different
types of TMDs of which 12 types present most commonly
(table).75 As this is a summary table the list is not exhaustive.
We believe that the easiest way to recall these 12 separate TMDs
is to subdivide them into four main categories or groups:
myalgia, arthralgia, intra-articular disorders, and headache
attributable to TMDs. Full details on DC/TMD diagnostic
algorithms and their sensitivity and specificity (where
determined) are available in an open access publication75 and
on the RDC/TMD consortium’s website (table).
The concept of eliciting pain that is “familiar” by provocation
underpins the new revised and validated diagnostic criteria for
TMD.75 Familiar pain is the process of recreating the patients’
symptoms during an examination and confirming with them
that this is what they experience. The following features on
examination should raise suspicion of, but do not formally
confirm or exclude, a diagnosis of painful TMD: provocation
of familiar pain through palpation of masseter and or temporalis
(fig 1), through palpation of the temporomandibular joint (fig
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2), or by putting the joint through its normal range of
movements.
Of note in the diagnostic algorithm of the DC/TMD is the
rationalised, limited, use of either plain or computed imaging
(employing ionising radiation), which is outlined on the
consortium’s website (table). Generally, imaging is only
performed if clinical examination indicates a functional problem.
Great care should be taken when explaining the results of any
imaging to patients as the use of words such as “degenerative”
may cause great concern and consequently affect patients’
behaviour.
Axis 2
Axis 2 of the DC/TMD can be used in a shortened form (a brief
screening axis for psychosocial comorbidity) or in its full form
(a comprehensive axis for psychosocial comorbidity). The
instruments comprising axis 2 are available in full on the
consortium’s website. Axis 2’s focus on psychosocial
comorbidity is because this is known to impact on prognosis
and treatment outcome.5 45 77
What are the red flags?
Box 1 outlines some of the red flags that maymimic a TMD,78-81
although this is not an exhaustive list. These red flags can act
as signposts for conditions to consider in differential diagnoses.
Specialties that will help in the case of relevant oral and
maxillofacial red flag symptoms include oral medicine, oral and
maxillofacial surgery, and oral surgery. Referral to ear, nose,
and throat surgeons should be considered for worrisome signs
in these areas and referral to a headache neurologist should be
considered for upper face pain.
What makes TMDs more likely to become
a chronic musculoskeletal pain?
Box 2 describes the factors that are more likely to be associated
with chronic pain.83-87
For patients with a noted affective problem in addition to the
pain or where there is a preoccupation with somatic symptoms
and experiences, referral to a clinical psychologist or psychiatrist
is an important adjunctive pain management option.89
Convincing evidence shows that psychosocial factors are
influential in the development of general chronic pain states90
and of TMD specifically.5 45 77
Importantly, research has shown that a chronic pain trajectory
can be modified. People with acute TMDs identified as being
at high risk of chronic TMDs have been shown to benefit
considerably from early psychological intervention.91 This
suggests that although mood disorder, pain catastrophising,
somatic preoccupation, and poor coping skills may predispose
people with acute TMDs to develop long term problems,
intervening with appropriate psychological input before these
problems become entrenched can be of great value.
What is the management?
The recurring theme in the systematic reviews examined for
this review (see supplementary table) is that well designed
pragmatic randomised controlled trials using standardised and
patient based outcome measures in TMD are urgently needed.
An international consensus reached in 1995 and revised slightly
in 201027 92 was that reversible, conservative treatments should
generally form the first line intervention for TMDs. This is
based on data that suggest between 75% and 90% of patients
with TMDswill respond to these simpler, potentially less costly,
and much less invasive techniques.93 After an initial diagnosis
of acute TMD the first approach to management should be a
careful explanation of the (provisional) diagnosis alongside
education about the condition and its largely benign course.
This can be supplemented by advice on appropriate, time
limited, simple analgesic use and altered dietary consistency
for acute exacerbations plus information on self management
techniques.
Reversible and conservative treatments
Education—education about the condition and reassurance of
its benign and usually non-progressive nature can be helpful.
Lack of, or uncertainty in, diagnosis for patients with TMD has
a major impact on their quality of life and can lead to care
pathways that are not efficacious and possibly compound or
worsen symptoms.11 12 94 Health professionals should seek to
explain a clear (provisional) diagnosis to patients at the earliest
opportunity and then signpost helpful information and supportive
organisations. Providing diagrams to increase knowledge of the
anatomy are useful. Education would be the starting point for
management of any patient with a suspected TMD. Useful
resources to help with this are signposted in the additional
educational resources box.
Self management (or self care) techniques—specific suggestions
for self management and for physiotherapy are given in the
recently published primary care guidance for TMDs (www.
rcseng.ac.uk/fds/publications-clinical-guidelines/clinical_
guidelines/documents/temporomandibular-disorders-guideline-
2013). Simple generic advice around sleep hygiene, caffeine
consumption, and avoidance of parafunctional activities such
as daytime clenching, nail biting, or excessive chewing of gum
can be helpful. This advice along with suggestions on relaxation
techniques such as diaphragmatic breathing, and local measures
for pain relief such as the use of covered ice or warm flannels
to painful areas can be of benefit for some patients.
Physiotherapy and acupuncture—there is limited evidence to
suggest that physiotherapeutic modalities such as massage or
targeted exercises may help provide short term relief for acute
TMDs, although the results of a Cochrane systematic review
(see supplementary table) are awaited. A systematic review on
acupuncture suggests that it may reduce pain intensity and
specifically help with masseteric tenderness (see supplementary
table).
Cognitive behavioural therapy—such treatment is considered
the ideal psychological treatment for chronic pain.95 Cognitive
behavioural treatment for pain is an active, structured,
collaborative therapy, which aims to teach patients the most
adaptive ways of coping with their pain. Techniques might
include dealing with pain related anxieties, behavioural
activation plans, management of pain flare-ups, sleep hygiene,
and optimal communication strategies with family members.
The evidence for cognitive behavioural treatment in relation to
TMDs indicates important long term improvements in pain
intensity and mood, and reductions in activity limitation due to
pain.96 97 Cognitive behavioural treatment does not seem to
reduce pain on muscle palpation.
Splints—“mouth guards” in either a soft polyethylene or a hard
acrylic that provide full coverage of all the upper or lower teeth
worn, can be worn at night in those who grind or clench their
teeth. Mouth guards help to protect tooth substance and may
also provide an element of biofeedback.
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Box 1 Red flags that may mimic TMDs
• History of malignancy—potential for a new primary, recurrence, or metastases
• Presence of lymphadenopathy or neck masses—consider a neoplastic, infective, or autoimmune cause
• Sensory or motor function changes (specifically focusing on cranial nerves V, VII, and VIII)—consider intracranial causes, or malignancy
affecting the nerve’s peripheral branches
• Recurrent epistaxis, purulent nasal drainage, or anosmia—consider nasopharyngeal carcinoma or chronic sinusitis
• Trismus especially if history of using paan or betel nut—consider oral malignancy as part of differential diagnoses and think about
employing the “Trismus checklist”82
• Unexplained pyrexia or weight loss—consider malignant tumours, immunosuppression, and infective causes as part of differential
diagnoses
• First episode in over 50s, unilateral headache accompanied by jaw claudication, and general malaise—consider temporal arteritis
• Facial asymmetry or masses (uncommon in TMD unless there is masseteric hypertrophy)—consider neoplastic, infective, or inflammatory
causes
• Occlusal changes (bite of teeth changes) as determined by dentist that do not predate the start of the TMD—consider growth disturbance
of condyle, neoplasia, rheumatoid arthritis, and traumatic causes as part of differential diagnoses
• Ipsilateral objective change in hearing—consider acoustic neuroma, or other ear disease as part of differential diagnoses
• Persisting or worsening symptoms despite treatment—consider a misdiagnosis or more complex case
• History of recent head and neck trauma
• Paroxysmal unilateral lancinating pain with or without autonomic features—more likely to be associated with trigeminal neuralgia or
one of the trigeminal autonomic cephalagias
Box 2 Factors associated with pain from TMDs becoming chronic
• Females with myogenous TMD
• Increasing age at presentation
• Graded chronic pain scale88 score of 3 or 4
Higher pain intensity
Higher pain interference
• More widespread non-specific symptoms (or higher number of pain locations)
• Concurrent psychiatric diagnosis or mood disturbance (depression, anxiety, anger)
Simple analgesia—non-steroidal anti-inflammatory drugs can
be used, being mindful of gastrointestinal side effects from
continual use and drug overuse headache.
Other drug interventions—more “advanced” approaches include
the use of neuromodulatory agents for persistent pain, which
would all come under off-label prescribing. A small number of
published trials support the use of gabapentin, benzodiazepines,
amitriptyline, and propranolol for the management of pain of a
myogenous origin.60 98-100Botulinum toxin applied to the muscles
of mastication has been the subject of a small number of
randomised controlled trials of varying quality and with the
potential for type II errors.101-104 Considering the results of these
various studies as a whole the evidence at present is at best
equivocal for the use of botulinum toxin in myogenous TMDs,
but there is still a need for a definitive and appropriately
powered randomised controlled trial.105 Some concerns are
emerging from a small scale study about the potential osteopenic
effects on the temporomandibular joint of repeatedly
administered botulinum toxin to the muscles of mastication over
a long period.106
Irreversible approaches
The American Association for Dental Research has also issued
a statement to recommend strongly that unless there are “specific
and justifiable indications,” irreversible approaches should not
be used as primary management for TMDs.27
Orthodontics and occlusal equilibration—systematic reviews
of irreversible approaches such as orthodontics and occlusal
equilibration (careful grinding of the natural teeth to achieve a
more “harmonious” bite) show these approaches lack evidence
to support their use in the management of TMDs.107 108
Surgical interventions—these are only indicated in a small
number of cases and only if there is an intra-articular disorder,
degenerative joint disease, or other evident disease affecting
the temporomandibular joint.96
Why is psychological management of
TMDs important?
TMDs, as with other causes of pain, are best conceptualised in
biopsychosocial terms.109 The patient’s beliefs, expectations,
emotional state, family environment, and cultural background
can all play a role in the onset, development, and maintenance
of persistent pain. The axis 2 classification of the DC/TMD
explicitly recognises the importance of psychological and social
aspects of pain by assessing not just pain intensity but also
depressed mood, anxiety, pain related disability, parafunctional
behaviours, and a variety of associated comorbidities. The
DC/TMD also helps to perform a basic (“screening”) or a
“comprehensive” assessment of the patient’s psychosocial status
and can be used to inform referrals for specialised psychological
input.
In addition to cognitive behavioural therapy, there is limited
evidence for a range of other psychologically based interventions
for TMDs, including electromyographic biofeedback, stress
management, and hypnosis.96 97 In the past, referral for
psychological therapy has tended to be the last resort, once all
biological treatments have been exhausted and present treatment
“failed.” As a result of this type of approach patients may
interpret the referral to a psychologist as an indication that their
medical or dental practitioner has given up on them, or that their
pain is considered to be “psychological” and somehow not
genuine.110 Making time for adequate explanation of the
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multidisciplinary nature of complex pain treatment as early as
possible in the diagnosis and management process is generally
time well spent.
Having laid the groundwork that chronic pain is best managed
using a team approach (which includes the patient as an active
member of the team), the literature relating to facilitating the
engagement of patients in biopsychosocial intervention offers
several useful suggestions.111 As always, the quality of
patient-provider communication is important, with empathy for
the patient’s pain experience particularly relevant.112 The use of
patient centered communication skills, promoting patient self
efficacy, and providing positive feedback on patient’s coping
efforts can all enhance patient motivation to engage in self
management approaches.111 A further communication problem
for clinicians relates to patients wanting to pursue treatment
options that are risky, ill advised, or dangerous, such as an
irreversible intervention where there is no objective clinical
evidence to support its use. These requests are best understood
as reflecting the patient’s desperation in living with intractable
pain. In response, clinicians should firstly empathise with the
difficulty of the patient’s situation, but provide a clear, evidence
based explanation as to the inadvisability of the treatment.
Encouraging patients to refrain from falling into the trap of
seeking “quick fixes” for complex problems and assisting and
supporting them to develop and expand their own coping
resources, offers a better long term solution.
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Table
Table 1| Summary of salient history and examination findings for 12most common (numbers in parentheses) temporomandibular disorders62
Summary history and examination findingsSubcategoryCategory
Pain local to palpation; pain within body of muscle; pain spreads
outside the body muscle
Local myalgia (2); myofascial pain (3);
myofascial pain with referral (4)
Myalgia (1): history positive for both of following: pain
in jaw, temple, in ear, or in front of ear; pain modified
with jaw movement, function, or parafunction.
Examination: pain in masseter or temporalis produced
by palpation or maximum assisted or unassisted
opening
Pain in temporomandibular joint region produced by one of: palpation
or assisted or unassisted jaw movements
Arthralgia (5): history as for myalgia
Click, pop, snap: on open and close (1 out of 3 movements), or one
of opening and closing plus a lateral movement; as above but history
of lock does not matter how long; history: decreased mouth opening
and inability to eat or interference with eating. Examination: maximum
assisted opening <40 mm; history as above but maximum assisted
opening >40 mm
Disc displacements: with reduction (6);
with reduction with intermittent locking
(7); without reduction with limited
opening (8); without reduction without
limited opening (9)
Intra-articular disorders
Crepitus in any movement, with relatively little painDegenerative joint disease (10)
History: lock open and self manipulation to achieve closureSubluxation (11)
History: headache in temple and modified with jaw movement,
function, or parafunction. Examination: familiar headache with
palpation temporalis or with jaw movements
Headache attributable to temporomandibular disorder
(12)*
*As determined in the Diagnostic Criteria for TMD. The
Diagnostic Criteria for TMD definition differs slightly
from that described in international classification of
headache disorders, version 3.
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Figures
Fig 1 Surface anatomy of temporalis and masseter muscles. Adapted from Standring 2008113
Fig 2 Surface anatomy of temporomandibular joint. Mouth closed (left) and mouth open (right). Adapted from Drake et al
2005114
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